Protocoll No. AS15 MEL-001 (MET) Studie 11373, Malignes Melanom, PRAME
Laufzeit: 01.01.2010 - 31.12.2015
Kurzfassung
An open dose-escal. Phase I/II study to assess the safety, immunogenicity a. clin. Actifity of recPRAME+AS15 Antigen spec. Cancer Immunotherap. As first-line treatment of patients with PRAME pos. Metastatic melanoma
